The pill that opened the epidemic
IUPAC: (5R,9R,13S,14S)-4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one · C18H21NO4 · MW 315.37 g/mol · CAS 76-42-6 · usually the HCl salt
Oxycodone. A semisynthetic morphinan opioid — synthesized from thebaine, a minor poppy alkaloid — and a full µ-opioid receptor (MOR) agonist. Where morphine is the natural template, oxycodone is the engineered, orally reliable version: the 14-hydroxy and 6-keto modifications hand it higher oral bioavailability and roughly 1.5× the oral potency of morphine. Brand/context names: OxyContin, Percocet (with acetaminophen), Percodan, Roxicodone, "oxy", "OC", "hillbilly heroin", "percs".
Oxycodone is a full agonist at the µ-opioid receptor (MOR), a class-A GPCR coupled to inhibitory Gi/o proteins. Binding the orthosteric pocket in the receptor's active state, it triggers Gαi/o dissociation that inhibits adenylyl cyclase (cAMP ↓), while the Gβγ subunit opens GIRK potassium channels (hyperpolarization) and closes voltage-gated Ca²⁺ channels (reduced neurotransmitter release). The net effect is presynaptic and postsynaptic silencing of nociceptive and other circuits — analgesia, euphoria, sedation, and, critically, brainstem respiratory suppression.
Oxycodone occupies the same pocket resolved in active-state MOR structures (PDB 5C1M, MOR + agonist BU72). The protonated tertiary amine forms the conserved salt bridge to Asp1473.32; the phenol/methyl-ether and 6-keto groups anchor the morphinan scaffold. Human MOR Ki ≈ 12 nM (ChEMBL).
Like most classical morphinans, oxycodone couples primarily through Gi/o. cAMP ↓, GIRK ↑, CaV ↓. β-arrestin2 recruitment and receptor internalization are modest relative to enkephalins — a determinant of tolerance kinetics rather than a "biased" selling point.
Oxycodone is MOR-selective. Real binding: δ-opioid (DOR) Ki ≈ 490–1,090 nM and κ-opioid (KOR) Ki ≈ 325–2,660 nM — roughly 40–200× weaker than MOR. At therapeutic exposure the DOR/KOR contribution is minor; the analgesia and the danger are MOR.
MOR agonism in the pre-Bötzinger complex and parabrachial/Kölliker-Fuse nuclei of the brainstem blunts CO₂ chemosensitivity and respiratory rhythm. This is the mechanism of opioid death: breathing slows and stops. It is dose-dependent and additive with any other CNS depressant.
CYP2D6 O-demethylates a fraction of oxycodone to oxymorphone, itself a marketed opioid with much higher MOR affinity (sub-nM–low-nM). Its systemic contribution to analgesia is debated (small fraction, ~11%), but it is genuinely a potent MOR agonist — relevant in CYP2D6 ultrarapid metabolizers.
As a full agonist, oxycodone has no analgesic or respiratory ceiling (unlike partial agonist buprenorphine). Increasing dose increases effect until the brainstem stops driving respiration — which is why tolerance loss after abstinence is lethal.
Oxycodone's defining pharmacokinetic feature is high, predictable oral bioavailability (~60–87%), far better than morphine (~25%), because it escapes the heavy first-pass glucuronidation that cripples morphine. Absorption is rapid; onset for immediate-release (IR) is ~10–30 min with analgesia lasting 3–6 h. The controlled-release OxyContin formulation was engineered to give a biphasic release over ~12 h — the same total drug, delivered slowly. That "slowly" was defeated by simply crushing the tablet.
Metabolism cascade: Two hepatic CYP routes dominate. The major pathway is CYP3A4 N-demethylation to noroxycodone (weak MOR activity, ~45% of a dose). The pharmacologically interesting minor pathway is CYP2D6 O-demethylation to oxymorphone — low-yield (~11%) but a genuinely potent MOR agonist. Both feed into noroxymorphone. Terminal glucuronidation and renal excretion clear the rest.
Oxymorphone (marked ★) is a full MOR agonist in its own right and roughly an order of magnitude more potent than oxycodone at the receptor. In CYP2D6 ultrarapid metabolizers more oxymorphone is generated per dose (heightened effect and risk); in poor metabolizers or on CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) that route is throttled. The clinically larger interaction lever is CYP3A4: strong inhibitors (ritonavir, clarithromycin, ketoconazole, grapefruit) raise parent-drug exposure substantially, while inducers (rifampin, carbamazepine, St John's wort) drop it. The danger of these interactions is invisible until it isn't.
Oxycodone's effects are the textbook µ-opioid syndrome, mapped onto distinct circuits. Analgesia and euphoria are the sought effects; sedation, constipation, and respiratory depression are the inseparable rest of the package. Because it is a full agonist with clean oral kinetics, it produces a fast, reliable reward signal — which is exactly what makes it reinforcing.
MOR agonism in the dorsal horn (presynaptic Ca²⁺ block on primary afferents + postsynaptic hyperpolarization) attenuates nociceptive transmission, while MOR in the periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) engages descending inhibition. The result is potent, dose-scalable pain relief across nociceptive and visceral pain.
MOR on GABAergic interneurons in the ventral tegmental area (VTA) silences them; the loss of inhibition disinhibits dopaminergic projections to the nucleus accumbens, raising accumbal dopamine and generating euphoria and reinforcement. Repeated activation drives ΔFosB accumulation, incentive sensitization, and the neuroadaptations of dependence and craving.
Brainstem MOR blunts hypercapnic and hypoxic ventilatory drive (pre-Bötzinger complex, Kölliker-Fuse). Add miosis (Edinger-Westphal nucleus — the "pinpoint pupils" overdose sign), bradycardia, and hypotension. This is the lethal axis, and it is steeply dose-dependent and additive with other depressants.
Chronic MOR agonism drives cellular tolerance (cAMP superactivation, receptor desensitization) and physical dependence. Peripheral MOR in the enteric nervous system produces near-universal constipation with minimal tolerance. Abrupt cessation yields the classic withdrawal syndrome — dysphoria, sweating, myalgia, GI cramping, piloerection — deeply unpleasant but rarely fatal, unlike alcohol or benzodiazepine withdrawal.
Oxycodone itself dates to 1917 (Germany) and had been in clinical use for decades. What changed history was a delivery system: OxyContin, launched by Purdue Pharma in 1996, packed large oxycodone doses into a controlled-release tablet marketed — on thin evidence — as carrying a low addiction risk because of its slow release. That claim was false, and it was promoted aggressively.
The crushable flaw (1996–2010): The original controlled-release matrix could be defeated by crushing, chewing, or dissolving the tablet — converting a 12-hour dose into an immediate bolus for insufflation or injection. High unit doses (up to 80 mg, once 160 mg) made this especially dangerous. Non-medical use, addiction, and overdose climbed through the 2000s.
The 2010 reformulation (OP): Purdue replaced OxyContin with an abuse-deterrent version that turns into a viscous gel when wetted and resists crushing. Non-medical use of the reformulated pill fell — but demand did not vanish. Many users migrated to heroin, which was cheaper and available, and subsequently into the illicit fentanyl supply. The reformulation is a case study in how supply-side tweaks displace rather than dissolve dependence.
The lesson, honestly stated: the molecule was never the whole story. Prescribing culture, marketing, dose, and formulation were. Oxycodone is a legitimate, effective analgesic; the harm came from how it was sold and used, and abstinence-only responses pushed people toward deadlier drugs.
Oxycodone is a pre-organized ligand. The fused morphinan ring system — five rings
locked by the 4,5-epoxy bridge — is conformationally rigid, with only the N-methyl and 3-methoxy groups
offering rotational freedom. In FlexAID∆S terms this means a small ligand conformational-entropy
penalty on binding (−TΔS_conf,ligand is modest): the drug does not pay much entropy to
adopt its bound pose because it barely has alternative poses to give up.
The receptor is the flexible partner. Apo MOR samples an ensemble of inactive/intermediate conformations —
high pocket Shannon entropy, H_pocket spread across many microstates. Agonist binding
(captured in the active-state PDB 5C1M with BU72) selects and stabilizes one active conformation,
collapsing that distribution: ΔH_pocket < 0. This entropy collapse — a
rigid morphinan snapping a soft receptor into a single transducer-competent state — is the thermodynamic
fingerprint that distinguishes a genuine full agonist from a loose binder.
The measured human MOR Ki ≈ 12 nM implies ΔGbind ≈ −RT·ln(1/Ki) ≈ −10.8 kcal/mol at 310 K. In an enthalpy–entropy decomposition, the conserved Asp1473.32 salt bridge and epoxy/keto hydrogen-bond contacts supply the enthalpy, while the rigid scaffold keeps the ligand's own entropic cost low — the FlexAID∆S ΔS separation of the two partners is what a docking score should be reporting, not a single lumped number.
Evidence-based, non-moralistic. Opioid death is a respiratory event — it is slow, it is predictable, and it is reversible if someone is there with naloxone. Almost everything below is about not being alone and not stacking depressants.
| Target | Affinity (Ki) | Rel. | Action |
|---|---|---|---|
|
MOR
µ-opioid receptor (OPRM1)
|
≈ 12 nM
human; rat 8.9–43.6 nM
|
Full agonist | |
|
DOR
δ-opioid receptor (OPRD1)
|
≈ 490–1,090 nM
rat brain
|
Weak | |
|
KOR
κ-opioid receptor (OPRK1)
|
≈ 325–2,660 nM
guinea pig / rat
|
Weak | |
|
Oxymorphone
CYP2D6 metabolite · at MOR
|
sub-nM – low nM
~10× more potent than parent
|
Full agonist | |
|
σ1R
Sigma-1 receptor
|
> 10,000 nM
inactive
|
None |